BCL11B helps to define T-lineage in lymphomas/leukaemias with a mixed/ambiguous immunophenotype
Pathology · 2025-10 · 57 (6) · 746-752
DOI: 10.1016/j.pathol.2025.01.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology, 2025-10. Verfasst von Shuyu E und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Repressor Proteins, Biomarkers, Tumor, Tumor Suppressor Proteins, T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
BCL11B is a pan-T-cell transcription factor that plays a pivotal role in guiding T-cell differentiation and maturation. BCL11B is lineage specific, and its expression is confined to T cells; B, NK and myeloid cells are usually negative. In this study, we aim to explore the value of BCL11B in the diagnosis and differential diagnosis of lymphomas/leukaemias exhibiting an ambiguous immunophenotype or which simultaneously express both T- and B-cell markers. The study cohort included 23 cases with a mixed/ambiguous immunophenotype, including five cases of T-lymphoblastic leukaemia (T-ALL) with B-marker expression, 10 mature T-cell lymphomas either with B-marker expression or lacking the expression of most T markers, three diffuse large B-cell lymphomas with T-marker expression, one classic Hodgkin lymphoma positive for T-cell antigens, and four plasma cell neoplasms expressing T markers. Immunohistochemistry (IHC) analysis for BCL11B was performed using formalin-fixed, paraffin-embedded tissue sections. All five cases of T-ALL were positive for BCL11B, confirming T-lineage. Amongst 10 cases of mature T-cell lymphoma, eight were BCL11 positive, and the remaining two BCL11B-negative cases were anaplastic large-cell lymphoma (ALCL). All cases of B-cell lymphoma, classic Hodgkin lymphoma, and plasma cell neoplasm were negative for BCL11B, consistent with their non-T-lineage. In conclusion, BCL11B IHC is valuable in designating T-lineage in neoplasms with a mixed/ambiguous immunophenotype. As observed in this study, BCL11B expression is highly specific for T-cell lineage. Of note, the absence of BCL11B does not completely exclude a diagnosis of T-cell lymphoma or leukaemia, especially in cases with a potential diagnosis of ALCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wwang13@mdanderson.org.
Zitieren
APA
E, S., Vega, F., Khanlari, M., Fang, H., Xu, J., Li, S., Hu, S., Wang, S. A., Wei, Q., Wang, W. J., Medeiros, L. J., & Wang, W. (2025). BCL11B helps to define T-lineage in lymphomas/leukaemias with a mixed/ambiguous immunophenotype. Pathology, 57(6), 746-752. https://doi.org/10.1016/j.pathol.2025.01.010
Vancouver
E S, Vega F, Khanlari M, Fang H, Xu J, Li S, et al. BCL11B helps to define T-lineage in lymphomas/leukaemias with a mixed/ambiguous immunophenotype. Pathology. 2025;57(6):746-752. doi:10.1016/j.pathol.2025.01.010
BibTeX
@article{E2025,
author = {E, Shuyu and Vega, Francisco and Khanlari, Mahsa and Fang, Hong and Xu, Jie and Li, Shaoying and Hu, Shimin and Wang, Sa A and Wei, Qing and Wang, Wei J and Medeiros, L Jeffrey and Wang, Wei},
title = {BCL11B helps to define T-lineage in lymphomas/leukaemias with a mixed/ambiguous immunophenotype},
journal = {Pathology},
year = {2025},
volume = {57},
number = {6},
pages = {746--752},
doi = {10.1016/j.pathol.2025.01.010}
}
EUVIMED